Life Sciences Law & Industry Report connects the dots among the many disciplines that make up the burgeoning life sciences industry, with biweekly updates on current regulatory, legislative,...
Oct. 31 — Johnson & Johnson Oct. 28 appealed a district court’s decision invalidating claims of one of the patents covering its blockbuster arthritis treatment Remicade as Pfizer Inc. readies its Remicade biosimilar Inflectra for launch next month ( Janssen Biotech, Inc. v. Celltrion Healthcare Co., Ltd. , Fed. Cir., No. 15-01449, 10/28/16 ).
The U.S. District Court for the District of Massachusetts held Aug. 17 antibodies claimed in U.S. Patent No. 6,284,471, which expires in 2018, were already disclosed in an earlier patent ( 10 LSLR, 8/19/16 ). The Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) had earlier reached the same conclusion about the patent claims’ validity. J&J appealed the district court’s ruling to the U.S. Court of Appeals for the Federal Circuit.
These rulings, if affirmed, would effectively take away J&J’s argument that that Pfizer’s Inflectra infringes the patent. If the invalidity decisions are reversed and the patents are determined to have been infringed, Pfizer would likely be found to owe J&J licensing fees for Inflectra. Either way, the ultimate rulings will add another chapter to the growing history of biosimilar litigation.
J&J filed another suit against Pfizer and the Korean-based manufacturer Celltrion Inc. in the same federal district court for infringement of another Remicade-related patent, U.S. Patent No. 7,598,083, and a decision in that case is expected within a month.
J&J’s global revenues for Remicade (infliximab) reached their peak in 2014 at $10.4 billion and declined 2.4 percent in 2015 due to competition from European biosimilars.
A J&J spokeswoman told Bloomberg BNA in an Oct. 31 e-mail, “We will continue to defend our intellectual property rights and view Pfizer/Celltrion’s commercial launch prior to the outcome of these appeals to be an at-risk launch.” She added that J&J also is continuing the appeal process of the PTAB decision, for which opening arguments were held Sept. 28 and a decision is expected within the next three months. A Pfizer spokeswoman declined Bloomberg BNA’s e-mail request for comment.
A biosimilar is a biologic drug product that is highly similar to a Food and Drug Administration-approved biologic, such as Remicade. The Biologics Price Competition and Innovation Act provides an abbreviated approval pathway for biosimilars that partly relies on data submitted for FDA approval of the original biologic, also known as a reference product (RP). In April, the agency approved Celltrion’s Inflectra as a biosimilar of Remicade ( 10 LSLR, 4/15/16 ). Pfizer’s Hospira has exclusive U.S. marketing rights to Inflectra, which is made by Celltrion.The cost for a biosimilar is expected to be less than the RP because of reduced development costs as a result of the abbreviated approval pathway. Pfizer, in its announcement of the expected November launch, said Inflectra will be shipped at a 15 percent discount to current wholesale prices for Remicade.
To contact the reporter on this story: John T. Aquino in Washington at email@example.com
To contact the editor responsible for this story: Randy Kubetin at RKubetin@bna.com
The appeal documents are at http://src.bna.com/jKr.
Copyright © 2016 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)